



VIASKIN® PEANUT Selected for U.S. Consortium of Food Allergy Research's Peanut Allergy Desensitization Trial Funded by the NIH

Paris, France – 1 September, 2010 – DBV Technologies (DBV), a biotechnology company specializing in innovative products for the diagnosis and the treatment of food allergies, announced today that its lead product VIASKIN® PEANUT for Peanut Specific EPicutaneous ImmunoTherapy (EPIT) has been selected to be evaluated in a Phase II study led by the U.S. Consortium of Food Allergy Research (CoFAR).

This Phase II study in peanut allergy desensitization will be funded by a renewed five year grant from the U.S National Institutes of Health (NIH) and is expected to begin in mid 2011. The research program will be conducted at CoFAR clinical sites that have worldwide recognized expertise in food allergy and will last for a minimum of three years.

The NIH officially announced on the 14 July 2010 that a \$29.9 Million grant was awarded to the CoFAR, in particular to continue to foster new approaches to prevent and treat food allergies. As part of the proposed research programs, DBV Technologies' EPIT approach, specifically its Peanut Specific EPIT program using VIASKIN PEANUT, has been selected as an innovative desensitization treatment with sufficient scientific rationale to allow further clinical investigation.

DBV Technologies is currently conducting Phase Ib clinical trials with VIASKIN PEANUT in five U.S. clinical centers, of which three are sites already part of CoFAR.

Commenting on the announcement, DBV Technologies' CEO and Co-Founder, Pierre-Henri Benhamou, MD said: "To be selected in this food allergy research initiative funded by the NIH and led by the CoFAR, a group of outstanding leading food allergy specialists, is a significant endorsement of our EPIT desensitization approach. Their support in undertaking a long term clinical investigation with VIASKIN PEANUT is of immense value in developing a safe, painless and effective form of therapy for food allergy desensitization."

More information about DBV Technologies' Peanut Specific EPicutaneous ImmunoTherapy (EPIT) program can be found at: <http://www.dbv-technologies.com/viaskin-peanut.asp>

The Mount Sinai School of Medicine announcement can be found at: <http://www.mssm.edu/about-us/news-and-events/mount-sinai-continues-to-lead-research-on-food-allergy-with-renewed-nih-grant-of-299-million>